Photodynamic Therapy in Treating Patients With Resectable Non-Small Cell Lung Cancer That Has Spread to the Pleura
RATIONALE: Photodynamic therapy uses a drug, such as porfimer sodium, that is absorbed by tumor cells. The drug becomes active when it is exposed to light. When the drug is active, tumor cells are killed. Giving photodynamic therapy during surgery may kill any tumor cells that remain after surgery. PURPOSE: This phase II trial is studying the side effects and how well photodynamic therapy given during surgery works in treating patients with resectable non-small cell lung cancer that has spread to the pleura.
Checked against the public recordLast updated Nov 24, 2020 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Treatment
- Study type
- Interventional
- Phase
- Phase 2
- Sponsor
- Abramson Cancer Center at Penn Medicine
- Interventions being studied
- Drug: chemotherapy; Drug: porfimer sodium; Other: immunohistochemistry staining method; Other: laboratory biomarker analysis; Procedure: spectroscopy; Procedure: therapeutic conventional surgery
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
DISEASE CHARACTERISTICS: * Histologically confirmed non-small cell lung cancer (NSCLC) * Must have clinical and/or pathological evidence of pleural spread * Primary tumor must be resectable as assessed by the attending thoracic surgeon * Patients who have received or are currently receiving two-to-four courses of standard front-line chemotherapy are eligible PATIENT CHARACTERISTICS: * Must be medically fit to tolerate surgery * No CTCAE v3.0 grade III-IV elevations in liver transaminases * Bilirubin ≤ 1.5 mg/dL * No known HIV infection * Not pregnant or nursing PRIOR CONCURRENT THERAPY: * See Disease Characteristics * No prior treatment for NSCLC except pleurodesis or standard front-line chemotherapy * No prior pemetrexed disodium chemotherapy * No prior mantle radiotherapy * No concurrent chemotherapy or radiotherapy during the active study treatment period * Post-operative radiotherapy will be administered as clinically indicated
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- Abramson Cancer Center of the University of PennsylvaniaPhiladelphia, Pennsylvania
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Nov 24, 2020. Always confirm current availability with the study team.